Predicted HLA A∗0201 peptides for HHV-8 lytic cycle proteins
| HHV-8 protein . | Rank . | Position . | Sequence . | Binding score* . | Binding to T2 cells† . |
|---|---|---|---|---|---|
| gB | 1 | 649 -657 | RLASSVFDL | 285 | Neg |
| 2 | 492 -500 | LMWYELSKI | 245 | Pos | |
| 3 | 560 -568 | FLNSSNLFT | 189 | Pos | |
| 4 | 467 -505 | KIRDGINQV | 174 | Pos | |
| 5 | 9 -17 | TLGTVILLV | 160 | Pos | |
| gH | 1 | 440 -448 | KLMLDIHTV | 2072 | Pos |
| 2 | 310 -318 | FLVLFQMLV | 1216 | Pos | |
| 3 | 315 -323 | QMLVAHFLV | 1078 | Neg | |
| 4 | 705 -713 | ALFLILSFI | 488 | Neg | |
| 5 | 412 -420 | SILEGIAMV | 334 | Pos | |
| MCP | 1 | 501 -509 | YMGKNVAFV | 2923 | Neg |
| 2 | 244 -252 | MLSDMLAAV | 1115 | Neg | |
| 3 | 173 -181 | GLVDTVLAV | 656 | Neg | |
| 4 | 233 -241 | LMTRGKQYV | 470 | Neg | |
| 5 | 1046 -1054 | VLAEHILYC | 438 | Pos | |
| MiCP | 1 | 103 -111 | FQWDSNTQL | 339 | Pos |
| 2 | 203 -211 | VLDDLSMYL | 328 | Pos | |
| 3 | 65 -73 | YLSKCTLAV | 320 | Pos | |
| 4 | 210 -276 | YLCILSALV | 320 | Pos | |
| 5 | 268 -276 | VMFSYLQSL | 223 | Neg | |
| IE | 1 | 130 -138 | IILDTAIFA | 1356 | Neg |
| 2 | 195 -203 | LLLAFVLTI | 574 | Neg | |
| 3 | 98 -106 | GLQTLGAFV | 383 | Neg | |
| 4 | 162 -170 | ALIKQVAYL | 270 | Pos | |
| 5 | 135 -143 | AIFVCNAFV | 195 | Neg |
| HHV-8 protein . | Rank . | Position . | Sequence . | Binding score* . | Binding to T2 cells† . |
|---|---|---|---|---|---|
| gB | 1 | 649 -657 | RLASSVFDL | 285 | Neg |
| 2 | 492 -500 | LMWYELSKI | 245 | Pos | |
| 3 | 560 -568 | FLNSSNLFT | 189 | Pos | |
| 4 | 467 -505 | KIRDGINQV | 174 | Pos | |
| 5 | 9 -17 | TLGTVILLV | 160 | Pos | |
| gH | 1 | 440 -448 | KLMLDIHTV | 2072 | Pos |
| 2 | 310 -318 | FLVLFQMLV | 1216 | Pos | |
| 3 | 315 -323 | QMLVAHFLV | 1078 | Neg | |
| 4 | 705 -713 | ALFLILSFI | 488 | Neg | |
| 5 | 412 -420 | SILEGIAMV | 334 | Pos | |
| MCP | 1 | 501 -509 | YMGKNVAFV | 2923 | Neg |
| 2 | 244 -252 | MLSDMLAAV | 1115 | Neg | |
| 3 | 173 -181 | GLVDTVLAV | 656 | Neg | |
| 4 | 233 -241 | LMTRGKQYV | 470 | Neg | |
| 5 | 1046 -1054 | VLAEHILYC | 438 | Pos | |
| MiCP | 1 | 103 -111 | FQWDSNTQL | 339 | Pos |
| 2 | 203 -211 | VLDDLSMYL | 328 | Pos | |
| 3 | 65 -73 | YLSKCTLAV | 320 | Pos | |
| 4 | 210 -276 | YLCILSALV | 320 | Pos | |
| 5 | 268 -276 | VMFSYLQSL | 223 | Neg | |
| IE | 1 | 130 -138 | IILDTAIFA | 1356 | Neg |
| 2 | 195 -203 | LLLAFVLTI | 574 | Neg | |
| 3 | 98 -106 | GLQTLGAFV | 383 | Neg | |
| 4 | 162 -170 | ALIKQVAYL | 270 | Pos | |
| 5 | 135 -143 | AIFVCNAFV | 195 | Neg |
The estimated half-time of dissociation (T1/2 dis) of MHC class I complexes containing the peptide at 37°C at pH 6.5. Control peptides HIV-1 Gag263-272(KRWIILGLNK) and FLU M158-66 (GILGFVFTL) had T1/2 dis = 0 and 551, respectively.
Concentration-dependent binding of the peptides to T2 cells loaded at concentrations of 1, 10, 50, and 100 μg/mL. Positive binding was defined as greater than the mean + 3 SD of binding of the Gag263-272 peptide to the T2 cells.